Innovation Pharmaceuticals Inc (IPIX)

[sunspotter]

"Are you thinking he should have failed to provide the results as "anticipated" when he had them in hand, and instead wait until the "Additional analysis of topline and all study endpoints" was complete when it still seems not to be complete almost 2 months later?"

The truth is that the other analyses would have been available simultaneously or at the most a couple of days after the topline data (that's just the way that statistical analysis packages work).

Leo Ehrlich has known the results of the other analyses for a long time now.

The fact he hasn't released a PR about them suggest they were just as negative as the primary endpoints.

We can reach the same conclusion about the Compassionate Use program - the absence of the rumor mill and share price appreciation that invariably occurs when clinicians see unexpectedly good results from a CU program together with the absence of a PR from Ehrlich tells us that too was a complete bust.

I suspect brilacidin's mechanism of action is entirely related to the in vitro environment and simply does not translate to in vivo.

That's actually pretty common for COVID 19 candidates.